Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy

Canakinumab is a fully human monoclonal antibody that specifically neutralizes human interleukin (IL)-1β and has been approved by the US Food and Drug Administration for treating different types of autoinflammatory disorders such as cryopyrin-associated periodic syndrome, tumor necrosis factor recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Wen-Wei, Lu, Yun-Chi, Huang, Bo-Cheng, Chuang, Chih-Hung, Cheng, Yi-An, Chen, I.-Ju, Liu, Hui-Ju, Ho, Kai-Wen, Liao, Tzu-Yi, Liu, En-Shuo, Wu, Ting-Yi, Chang, Long-Sen, Hong, Shih-Ting, Cheng, Tian-Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295355/
https://www.ncbi.nlm.nih.gov/pubmed/34290297
http://dx.doi.org/10.1038/s41598-021-94298-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295355/
https://www.ncbi.nlm.nih.gov/pubmed/34290297
http://dx.doi.org/10.1038/s41598-021-94298-y

Ejemplares similares